Upregulated expression of FGF13/FHF2 mediates resistance to platinum drugs in cervical cancer cells

Scientific Reports

Volumn 3, Issue , 2013, Pages

  Okada, Tomoko ^a   Murata, Kazuhiro ^a,b   Hirose, Ryoma ^a,c   Matsuda, Chie ^a   Komatsu, Tsunehiko ^b   Ikekita, Masahiko ^c   Nakawatari, Miyako ^d   Nakayama, Fumiaki ^d   Wakatsuki, Masaru ^e   Ohno, Tatsuya ^e,f   Kato, Shingo ^e,g   Imai, Takashi ^d   Imamura, Toru ^a,c  

^a NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

^b TEIKYO UNIVERSITY CHIBA MEDICAL CENTER   (Japan)

^c TOKYO UNIVERSITY OF SCIENCE   (Japan)

^d NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^e NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^f GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 13; MESSENGER RNA;

ADULT; ALTERNATIVE RNA SPLICING; ARTICLE; CANCER STAGING; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; HELA CELL LINE; HUMAN; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; TREATMENT OUTCOME; TUMOR CELL LINE; UPREGULATION; UTERINE CERVIX TUMOR;

ADULT; ALTERNATIVE SPLICING; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HELA CELLS; HUMANS; MIDDLE AGED; NEOPLASM STAGING; RNA, MESSENGER; TREATMENT OUTCOME; UP-REGULATION; UTERINE CERVICAL NEOPLASMS;

EID: 84885621624     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep02899     Document Type: Article

References (30)

1. Goldfarb, M. Fibroblast growth factor homologous factors: Evolution, structure, and function. Cytokine Growth Factor Rev. 16, 215-220 (2005). (Pubitemid 40616118)
2. Schoorlemmer, J. & Goldfarb, M. Fibroblast growth factor homologous factors are intercellular signaling proteins. Curr. Biol. 11, 793-737 (2001).
3. Itoh, N. & Ornitz, D. M. Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease. J. Biochem. 149, 121-130 (2011).
4. Schoorlemmer, J. & Goldfarb, M. Fibroblast growth factor homologous factors and the islet brain-2 scaffold protein regulate activation of a stress-activated protein kinase. J. Biol. Chem. 277, 49111-49119 (2002). (Pubitemid 36014339)
5. Wu, Q. F. et al. Fibroblast growth factor 13 is a microtubule-stabilizing protein regulating neuronal polarization and migration. Cell 149, 1549-1564 (2012).
6. Olsen, S. K. et al. Fibroblast growth factor (FGF) homologous factors share structural but not functional homology with FGFs. J. Biol. Chem. 278, 34226-34236 (2003). (Pubitemid 37553265)
7. Barnes, K. R. & Lippard, S. J. Cisplatin and related anticancer drugs: recent advances and insights. Met. Ions Biol. Syst. 42, 143-177 (2004).
8. Zhang, C. X. & Lippard, S. J. New metal complexes as potential therapeutics. Curr. Opin. Chem. Biol. 7, 481-489 (2003). (Pubitemid 36980839)
9. Wang, D. & Lippard, S. J. Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discov. 4, 307-320 (2005). (Pubitemid 41130944)
10. Perego, P. et al. Development of resistance to a trinuclear platinum complex in ovarian carcinoma cells. Int. J. Cancer 105, 617-624 (2003). (Pubitemid 36687728)
11. Siddik, Z. H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22, 7265-7279 (2003). (Pubitemid 37487159)
12. Kelland, L. R. Preclinical perspectives on platinum resistance. Drugs 59, 1-8 (2000). (Pubitemid 30344986)
13. Chen, H. & Kuo, M. T. Role of glutathione in the regulation of cisplatin resistance in cancer chemotherapy. Metal-Based Drugs e-pub 14 September 2010, doi:10.1155/2010/430939, (2010).
14. Munoz-Sanjuan, I., Smallwood, P. M. & Nathans, J. Isoform diversity among fibroblast growth factor homologous factors is generated by alternative promoter usage and differential splicing. J. Biol. Chem. 275, 2589-2597 (2000). (Pubitemid 30082025)
15. Okada, T. et al. Mononuclear platinum(II) complex with 2-phenylpyridine ligands showing high cytotoxicity against mouse sarcoma 180 cells acquiring high cisplatin resistance. J. Med. Chem. 44, 661-4667 (2001).
16. Kuo, M. T., Fu, S., Savarai, N. & Chen, H. H. Role of the human high-affinity copper transporter in copper homeostasis regulation and cisplatin sensitivity in cancer chemotherapy. Cancer Res. 72, 4616-4621 (2012).
17. Samimi, G. et al. Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells. Clin Cancer Res. 10, 4661-4669 (2004). (Pubitemid 38955516)
18. Inoue, Y. et al. ATP7B expression is associated with in vitro sensitivity to cisplatin in non-small cell lung cancer. Oncol. Lett. 2, 279-282 (2010).
19. Stepien, K. M., Tomaszewski, M., Tomaszewska, J. & Czuczwar, S. J. The multipledrug transporter P-glycoprotein in pharmacoresistance to antiepileptic drugs. Pharmacol. Rep. 64, 1011-1019 (2012).
20. Huang, Y., Dai, Z., Barbacioru, C. & Sadée, W. Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance. Cancer Res 65, 7446-7454 (2005). (Pubitemid 41161279)
21. Sato, H., Tamba, M., Ishii, T. & Bannai, S. Cloning and expression of a plasma membrane cystine/glutamate exchange transporter composed of two distinct proteins. J. Biol. Chem. 274, 11455-11458 (1999).
22. Zhang, K., Chew, M., Yang, E. B., Wong, K. P. & Mack, P. Modulation of cisplatin cytotoxicity and cisplatin-induced DNA cross-links in HepG2 cells by regulation of glutathione-related mechanisms. Mol. Pharmacol. 59, 837-843 (2001). (Pubitemid 32274012)
23. Wittmack, E. K. et al. Fibroblast growth factor homologous factor 2B: association with Nav1.6 and selective colocalization at nodes of ranvier of dorsal root axons. J. Neurosci. 24, 6765-6775 (2004). (Pubitemid 38993898)
24. Wang, C., Chung, B. C., Yan, H., Lee, S.-Y. & Pitt, G. S. Crystal structure of the ternary complex of a NaV C-terminal domain, a fibroblast growth factor homologous factor, and calmodulin. Structure 20, 1167-1176 (2012).
25. Prudovsky, I. et al. The non-classical export routes: FGF1 and IL-1a point the way. J. Cell Sci. 116, 4871-4881 (2003). (Pubitemid 38016694)
26. Backhaus, R. et al. Unconventional protein secretion: membrane translocation of FGF-2 does not require protein unfolding. J. Cell Sci. 117, 1727-1736 (2004). (Pubitemid 38559305)
27. Nakayama, F. et al. Fibroblast growth factor-12 (FGF12) translocation into intestinal epithelial cells is dependent on a novel cell-penetrating peptide domain. J. Biol. Chem. 286, 25823-25834 (2011).
28. Asada, M., Honda, E. & Imamura, T. Construction of pcDNA3.1-based vectors with blasticidin and puromycin resistant markers. Anal. Biochem. 352, 305-307 (2006).
29. Iwakawa, M. et al. The radiation-induced cell-death signaling pathway is activated by concurrent use of cisplatin in sequential biopsy specimens from patients with cervical cancer. Cancer Biol. Ther. 6, 905-911 (2007). (Pubitemid 351574981)
30. Nakawatari, M. et al. Change in fibroblast growth factor 2 expression as an early phase radiotherapy-responsive marker in sequential biopsy samples from patients with cervical cancer during fractionated radiotherapy. Cancer 116, 5082-5092 (2010).